Bank of America just raised its EUR/USD forecast
SUNNYVALE, CA—Jami K. Nachtsheim, a director at Intuitive Surgical Inc . (NASDAQ:ISRG), executed a significant stock sale on May 1, 2025, according to a recent SEC filing. The transaction involved the sale of 2,400 shares of common stock at a price of $520.00 per share, amounting to a total of $1,248,000. The sale comes as Intuitive Surgical trades near $517, with a market capitalization of $186 billion and an overall "GREAT" financial health rating according to InvestingPro analysis.
On the same day, Nachtsheim also acquired 2,400 shares through the exercise of non-qualified stock options, priced at $90.4944 per share. This transaction was part of a pre-established trading plan compliant with SEC Rule 10b5-1, which is set to expire on December 10, 2025. Following these transactions, Nachtsheim holds 6,371 shares of Intuitive Surgical common stock directly. The stock has shown strong performance with a 37% return over the past year, though InvestingPro data indicates it’s currently trading at premium valuations with a P/E ratio of 75.
Additionally, Nachtsheim received 531 restricted stock units, which are set to vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent upon her continued service with the company. For deeper insights into insider trading patterns and comprehensive analysis of Intuitive Surgical, including 13 additional ProTips, explore the full research report available on InvestingPro.
In other recent news, Intuitive Surgical’s da Vinci (EPA:SGEF) Single Port (SP) surgical system received U.S. Food and Drug Administration (FDA) clearance for colorectal surgery, specifically for transanal local excision/resection. This approval enhances the system’s capabilities in minimally invasive procedures and is expected to improve patient outcomes. Additionally, Intuitive Surgical reported strong first-quarter earnings, surpassing expectations for both revenue and earnings per share, driven by a 17% increase in procedure volume. Analysts from Stifel maintained a Buy rating with a $670 target, highlighting the company’s robust procedure growth despite tariff concerns. RBC Capital adjusted its price target to $605 while maintaining an Outperform rating, acknowledging the company’s positive outlook on procedure growth and upcoming product launches. Truist Securities also revised its price target to $590, maintaining a Buy rating and noting the potential impact of tariffs on earnings per share. Piper Sandler reduced its price target to $575, maintaining an Overweight rating, and expressed confidence in Intuitive Surgical’s growth potential despite near-term challenges. These developments reflect Intuitive Surgical’s ongoing momentum and strategic advancements in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.